Content Editor [2]
Due to the public health risk surrounding the Coronavirus, the Bureau of Professional and Occupational Affairs is currently unable to accept walk-in customers and phone calls. For all inquiries, please utilize the email addresses found on the Board Contact Information webpage.
For more details visit:
Application for Reactivation of a Pharmacist License that has been Expired or Inactive for Less Than 4 Years (PDF)
Coronavirus Information
Learn more about the coronavirus (COVID-19) outbreak.
Information for telemedicine during the coronavirus emergency.
Message from DEA regarding COVID-19 (PDF)
Suggestions for Board of Pharmacy for Pharmacists:
In response to COVID-19 and potential shortages of medications that may be effective against the virus such as hydroxychloroquine, pharmacists should verify the patient is confirmed COVID-19 positive before dispensing. Patients established on therapy or utilizing the medication for other diagnoses (e.g. Lupus or Rheumatoid Arthritis) should be able to continue to access without diagnosis verification. Smaller quantities of hydroxychloroquine should be dispensed to COVID-19 patients when appropriate to prevent potential shortages.
State Board of Pharmacy
The Bureau of Professional and Occupational Affairs (BPOA) received reports that a person pretending to be from the State Board of Pharmacy (Board) is calling licensees about the status of their license. The scammer asks for credit card information. Persons who give their credit card information may not only lose their money, but also can become a victim of identity theft.
Licensees are urged to avoid becoming a victim of credit card fraud or identity theft:
BPOA and/or Board will NOT call licensees asking for payment over the phone.
If you get a text message or call asking for your credit card information, hang up.
Do NOT give your personal or financial information over the phone.
If you feel that you are a victim of any type of scam, you should immediately notify your local or state police.
Announcement for Pharmacist License Applicants
At the June 28, 2018
Pennsylvania State Board of Pharmacy (Board) Meeting, the Board voted to waive
the requirement that Pharm.D. graduates of schools of pharmacy accredited by
the Accreditation Council for Pharmacy Education (ACPE) earn at least 500
intern hours outside of their academic program. This means that the 1,500
intern hours required for licensure as a pharmacist may be earned through an
ACPE-accredited school of pharmacy’s Pharm.D. program and these graduates are
no longer required to earn 500 intern hours outside of the school’s academic
program.
United States Pharmacopoeia (USP) (Rev. 12/19)
At the October 22, 2019 Pennsylvania State Board of Pharmacy (Board) Meeting, the Board discussed issues related to USP’s decision to delay implementation of the revisions to chapters 795 and 797 pending resolution of appeals. The following decisions were approved by the Board and placed on record:
- The Board is enforcing USP 795 and 797 as currently written. Board Regulation Section 27.601 was finalized on June 22, 2019 and requires compliance with section 503a of the federal Food, Drug and Cosmetic Act, federal regulations promulgated thereunder and the current version of the USP chapters governing compounding.
- The Board is delaying the enforcement of USP 800 until the appeals of certain provisions of the revised USP 795 and 797 are resolved. While enforcement of USP 800 is being delayed, pharmacies should do their best to comply with the requirements of USP 800, including the sections related to the handling of hazardous medications, as these requirements will be enforced at some time in the future, dependent on resolution of the appeals of the revised USP 795 and 797.
-
The Board voted to adopt the following position and will be amending its regulations to reflect this information:
The definition of "compounding" does not include the unencumbered flavoring of conventionally manufactured medications provided that the flavors used are inert, tested and do not alter a medication’s concentration beyond USP’s accepted level of variance.
Note: Please refer to the following links for additional information on USP 800 and its scope (i.e. it would be applicable only when a practitioner is engaged in compounding):
https://www.usp.org/sites/default/files/usp/document/our-work/compounding/usp-800-context-for-implementation-fs.pdf
https://www.usp.org/sites/default/files/usp/document/our-work/compounding/faqs-usp-800.pdf
Please note that neither the Board/Commission, nor its staff or counsel, are permitted to provide legal advice or advisory opinions, including interpretations of the law or regulations, or any indication as to how the Board would vote on any given case or scenario. You are invited to contact a private attorney or professional organization for advice or guidance.